Valor202020212022202320242025TTMDespesas comerciais, gerais e administrativas11.29 B15.23 B18.42 B19.22 B19.98 B19.93 B—Pesquisa e desenvolvimento5.99 B9.74 B9.76 B10.94 B13.58 B14.23 B—Lucro operacional5.16 B1.06 B3.76 B8.19 B10 B13.74 B—Lucro não operacional, total———————Despesa com juros, líquida de juros capitalizados———————Receitas não operacionais, líquidas das despesas com juros———————Receitas/despesas incomuns———————Lucro antes dos impostos3.92 B265 M2.5 B6.9 B8.69 B12.4 B—Participação no lucro———————Impostos772 M380 M792 M938 M1.65 B2.17 B—Participação de minoritários52 M3 M5 M6 M6 M8 M—Outras receitas/despesas após impostos———————Lucro líquido antes das operações descontinuadas3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Operações descontinuadas———————Lucro líquido3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Ajuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas———————Lucro básico por ação———————Lucro diluído por ação———————Número médio de ações básicas———————Ações diluídas———————EBITDA———————EBIT———————Custo da receita5.3 B12.44 B12.39 B8.27 B10.21 B10.63 B—Outros componentes do custo———————Amortização e depreciação (fluxo de caixa)———————
AstraZeneca PLC - American Depositary Shares
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje.